Socioeconomic Status Mediates Racial Differences Seen Using the AT(N)Framework
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Objectives: African Americans are at greater risk for developing Alzheimer's disease (AD) dementia than non‐Hispanic whites. In addition to biological considerations (eg, genetic influences and comorbid disorders), social and environmental factors may increase the risk of AD dementia. This paper (1) assesses neuroimaging biomarkers of amyloid (A), tau (T), and neurodegeneration (N) for potential racial differences and (2) considers mediating effects of socioeconomic status (SES) and measures of small vessel and cardiovascular disease on observed race differences. Methods: Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magnetic resonance imaging (MRI), and resting state functional connectivity (rs‐fc) were collected from African American (n = 131) and white (n = 685) cognitively normal participants age 45 years and older. Measures of small vessel and cardiovascular disease (white matter hyperintensities [WMHs] on MRI, blood pressure, and body mass index [BMI]) and area‐based SES were included in mediation analyses. Results: Compared to white participants, African American participants had greater neurodegeneration, as measured by decreased cortical volumes (Cohen's f2= 0.05,p< 0.001). SES mediated the relationship between race and cortical volumes. There were no significant race effects for amyloid, tau, or rs‐fc signature. Interpretation: Modifiable factors, such as differences in social contexts and resources, particularly area‐level SES, may contribute to observed racial differences in AD. Future studies should emphasize collection of relevant psychosocial factors in addition to the development of intentional diversity and inclusion efforts to improve the racial/ethnic and socioeconomic representativeness of AD studies. ANN NEUROL 2021;89:254–265
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Social conditions as fundamental causes of disease.
Link, B. G., & Phelan, J. (1995) · Journal of Health and Social Behavior · doi:10.2307/2626958 · Cited by 5,722
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“For the polygenic risk score (PRS) for AD, weighted scores were calculated by using a logarithm of base 2 transformation on single nucleotide polymorphisms (SNPs), as reported in the International Genomics of Alzheimer’s Project (IGAP) study.(29) SNPs utilized for the score had either a high genotyping rate (> 90%) or…”
MethodSelf-citationFunctional Network Organization of the Human Brain
Power, J. D., Cohen, A. L., Nelson, S. M., Wig, G. S., Barnes, K. A., Church, J. A., Vogel, A. C., Laumann, T. O., Miezin, F. M., Schlaggar, B. L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.006 · Cited by 4,124 · cited 1×
“The average intra-network and internetwork correlation for each of the 13 previously described networks was computed yielding a 13 × 13 summary matrix for each individual.(42)”
MethodA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Self-citationTang, M.-X. (1998) · JAMA · doi:10.1001/jama.279.10.751 · Cited by 771
More than skin deep: Stress neurobiology and mental health consequences of racial discrimination
Berger, M., & Sarnyai, Z. (2015) · Stress · doi:10.3109/10253890.2014.989204 · Cited by 606
Brier, M. R., Thomas, J. B., Snyder, A. Z., Benzinger, T. L., Zhang, D., Raichle, M. E., Holtzman, D. M., Morris, J. C., & Ances, B. M. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5698-11.2012 · Cited by 595 · cited 9×
“© 2020 American Neurological Association254 genetics, and social determinants of health (SDOH) in studies of racial differences in AD.2–4”
BackgroundMethodSelf-citationBabulal, G. M., Quiroz, Y. T., Albensi, B. C., Arenaza‐Urquijo, E., Astell, A. J., Babiloni, C., Bahar‐Fuchs, A., Bell, J., Bowman, G. L., Brickman, A. M., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.009 · Cited by 528
Self-citationLifecourse Social Conditions and Racial and Ethnic Patterns of Cognitive Aging
Glymour, M. M., & Manly, J. J. (2008) · Neuropsychology Review · doi:10.1007/s11065-008-9064-z · Cited by 481
Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease
Chin, A. L., Negash, S., & Hamilton, R. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318211c6c9 · Cited by 416
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383 · cited 1×
“methods were previously published.(27,28) To control for effects of apolipoprotein ε4 (APOE ε4) on individuals in this analysis, APOE status was converted from a genotype to a binary variable.”
MethodSelf-citationWeuve, J., Barnes, L. L., Mendes de Leon, C. F., Rajan, K. B., Beck, T., Aggarwal, N. T., Hebert, L. E., Bennett, D. A., Wilson, R. S., & Evans, D. A. (2018) · Epidemiology · doi:10.1097/ede.0000000000000747 · Cited by 340
Effect of literacy on neuropsychological test performance in nondemented, education-matched elders
MANLY, J. J., JACOBS, D. M., SANO, M., BELL, K., MERCHANT, C. A., SMALL, S. A., & STERN, Y. (1999) · Journal of the International Neuropsychological Society · doi:10.1017/s135561779953302x · Cited by 250
Partial volume correction in quantitative amyloid imaging
Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247
Self-citationQuantitative Analysis of PiB-PET with FreeSurfer ROIs
Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246 · cited 1×
“2 years) of MRI using methodology previously described.(32,33) PET data were processed using the PET Unified Pipeline (github.”
MethodSelf-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Self-citationCruchaga, C., Del‐Aguila, J. L., Saef, B., Black, K., Fernandez, M. V., Budde, J., Ibanez, L., Deming, Y., Kapoor, M., Tosto, G., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.013 · Cited by 138 · cited 1×
“methods were previously published.(27,28) To control for effects of apolipoprotein ε4 (APOE ε4) on individuals in this analysis, APOE status was converted from a genotype to a binary variable.”
MethodSelf-citationWilkins, C. H., Schindler, S. E., & Morris, J. C. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1614 · Cited by 83 · cited 8×
“© 2020 American Neurological Association254 genetics, and social determinants of health (SDOH) in studies of racial differences in AD.2–4”
BackgroundInfluentialSelf-citationVascular aspects in Alzheimer’s disease
Skoog, I. (2000) · Advances in Dementia Research · doi:10.1007/978-3-7091-6781-6_6 · Cited by 71 · cited 4×
“Biophysical cohort differences, such as increased small vessel disease and cardiovascular risk factors, have been noted to be a more prevalent comorbidity for African Americans than Whites.(9,12,13) We also observed that African Americans had greater ADI values, indicating lower area-based SES, on average, compared to…”
BackgroundInfluentialSu, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152082 · Cited by 56 · cited 1×
“PET amyloid imaging was performed with either [(11)C] Pittsburgh Compound B (PiB) or [(18)F]-Flobetapir (AV45).(35,36) The time window for quantification was 30 to 60 minutes postinjection for PiB and 50 to 70 minutes for AV45.”
MethodSelf-citation
Cited by
Majoka, M. A., & Schimming, C. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.05.005 · Cited by 191
Alzheimer disease in African American individuals: increased incidence or not enough data?
Barnes, L. L. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00589-3 · Cited by 142
Gleason, C. E., Zuelsdorff, M., Gooding, D. C., Kind, A. J. H., Johnson, A. L., James, T. T., Lambrou, N. H., Wyman, M. F., Ketchum, F. B., Gee, A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12511 · Cited by 104
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
Metadata
- Authors
- Meeker, K. L., Wisch, J. K., Hudson, D., Coble, D., Xiong, C., Babulal, G. M., Gordon, B. A., Schindler, S. E., Cruchaga, C., Flores, S., Dincer, A., Benzinger, T. L., Morris, J. C., & Ances, B. M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-11-07
- Volume
- 89
- Issue
- 2
- Pages
- 254-265
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3097769967
- Cited by
- 68
- References
- 21
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.